Skip to main content

Our Mission

To improve the lives of people impacted by hypoparathyroidism through education, support, research, and advocacy. Learn more and get involved.

NEWS & EVENTS

For U.S. patients receiving NATPARA through the Special Use Program

For a limited time the presentations can be viewed here on the website.

AZP-3601 is currently in development for the treatment of hypoparathyroidism

The study will be conducted at the National Institutes of Health.